Thus, TMB may function as a biomarker for forecasting a positive response to immune checkpoint inhibitors.[27] According to a large-sample investigation, no significant association is found between PD-L1 expression and TMB across the majority of cancers, establishing them as independent biomarkers.[28] Both have the potential to predict the immunotherapy efficacy, and their combined use enables more accurate prediction of the immune checkpoint inhibitor efficacy. This evidence concerns the gene CD274 and cancer.